<DOC>
	<DOCNO>NCT02212015</DOCNO>
	<brief_summary>Open-label phase II trial investigate efficacy safety investigational combination pazopanib paclitaxel .</brief_summary>
	<brief_title>Evaluation Votrient Angiosarcoma</brief_title>
	<detailed_description>Open-label phase II trial investigate efficacy safety investigational combination pazopanib paclitaxel.This multi-center , open-label , prospective , single arm phase II study design evaluate clinical efficacy safety experimental combination pazopanib paclitaxel treatment patient advance metastatic angiosarcoma.The safety evaluation ( physical examination , laboratory check define protocol , toxicity/adverse event assessment accord Eastern Cooperative Oncology Group version 4.0 ) schedule every cycle day 1 , 8 , 15 29 ( = day 1 next cycle ) .</detailed_description>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects must provide write informed consent prior performance studyspecific procedures assessment must willing comply treatment followup . Note : Procedures conduct part subject 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol . Age ≥ 18 year Life expectancy &gt; 3 month Ability swallow tablet Histological confirm angiosarcoma , primary secondary angiosarcoma ( e.g . radiationinduced angiosarcoma chronical lymphedema ) eligible . Tumor must locally advance ( unresectable ) metastatic . A progression must document within 6month period prior screen . Eastern Cooperative Oncology Group performance status ≤ 2 At least one measurable skin lesion one measurable radiological ( CT MRI ) target lesion ( RECIST 1.1 ) Adequate organ system function describe protocol A female eligible enter participate study either non childbearing potential ( define protocol ) childbearing potential negative pregnancy test within 2 week prior first dose study drug agrees use adequate contraception ( define protocol ) study 30 day last dose study drug . All sexually active male patient must agree use adequate method birth control ( see protocol ) throughout study 30 day last dose study drug . Patients need active treatment another malignant disease angiosarcoma Prior treatment taxane within last 12 month study entry History clinical evidence central nervous system ( CNS ) metastases leptomeningeal sarcomatosis . ( see protocol ) Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding ( see protocol ) Clinically significant gastrointestinal abnormality may affect absorption investigational product ( see protocol ) Presence uncontrolled infection QT prolongation interval ( QTc ) &gt; 480 msec . Clinically significant cardiovascular disorder within past 6 month Major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer Poorly control hypertension ( see protocol ) Evidence active bleeding bleed diathesis Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel Uncontrolled seizure , disorder CNS psychiatric disorder may put patient safety risk , prevent give informed consent impact patient 's compliance use study medication Women pregnant breast feeding Patients able willing interrupt intake medication allow accord study protocol least 14 day start study medication whole study period Chemotherapy radiotherapy within 14 day start study medication Any ongoing toxicity prior anticancer therapy &gt; grade 1 and/or progress severity , except alopecia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>